Ensysce Biosciences Inc. (NASDAQ: ENSC) announced it has enrolled 50% of subjects targeted for interim review in its pivotal Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE